Computing with evidence. Part I: A drug-mechanism evidence taxonomy oriented toward confidence assignment

Journal of Biomedical Informatics

Volumn 42, Issue 6, 2009, Pages 979-989

  Boyce, Richard ^a   Collins, Carol ^b   Horn, John ^b   Kalet, Ira ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Drug safety; Drug drug interactions; Evidence taxonomy; Evidentialism; Knowledge representation

Indexed keywords

ACTIVE PHARMACEUTICAL INGREDIENTS; DRUG SAFETY; DRUG-DRUG INTERACTIONS; EVIDENCE MODEL; EVIDENCE TAXONOMY; EVIDENTIALISM; KNOWLEDGE BASE; REDUCTASE INHIBITORS; STATINS;

DRUG PRODUCTS; KNOWLEDGE BASED SYSTEMS; KNOWLEDGE REPRESENTATION; TAXONOMIES;

DRUG INTERACTIONS;

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ALGORITHM; ARTICLE; DRUG MECHANISM; DRUG RESEARCH; EVIDENCE BASED PRACTICE CENTER; INTERNET; KNOWLEDGE BASE; MEDICAL INFORMATICS; PRIORITY JOURNAL; TAXONOMY;

ALGORITHMS; CONFIDENCE INTERVALS; DATABASES, FACTUAL; DRUG INTERACTIONS; EVIDENCE-BASED MEDICINE; HUMANS; MEDICAL INFORMATICS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; TERMINOLOGY AS TOPIC;

EID: 70350571792     PISSN: 15320464     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbi.2009.05.001     Document Type: Article

References (48)

1. Committee on Identifying and Preventing Medication Errors. Preventing medication errors, Tech. rep. Institute of Medicine, 0309102685; 2006.
2. Gurwitz J., Field T., Judge J., Rochon P., Harrold L., Cadoret C., et al. The incidence of adverse drug events in two large academic long-term facilities. Am J Med 118 (2005) 251-258
3. Juurlink D.N., Mamdani M., Kopp A., Laupacis A., and Redelmeier D.A. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 289 13 (2003) 1652-1658
4. Chen Y.-F., Avery A., Neil K., Johnson C., Dewey M., and Stockly I. Incidence and possible causes of prescribing potential hazardous/contraindicated drug combinations in general practice. Drug Safety 28 (2005) 67-80
5. Preskorn S.H. How drug-drug interactions can impact managed care. Am J Managed Care 10 6 Suppl (2004) S186-S198
6. Miller R., Gardner R., Johnson K., and Hripscak G. Clinical decision support and electronic prescribing systems: a time for responsible thought and action. JAMIA 12 4 (2005) 365-376 pubMed ID:1590548
7. Hazlet T., Lee T.A., Hansten P., and Horn J.R. Performance of community pharmacy drug interaction software. J Am Pharm Assoc 41 2 (2001) 200-204 pubMed ID:1129733
8. Min F, Smyth B, Berry N, Lee H, Knollmann B. Critical evaluation of hand-held electronic prescribing guides for physicians. In: American Society for Clinical Pharmacology and Therapeutics, vol. 75. American Society for Clinical Pharmacology and Therapeutics; 2004.
9. Smith W.D., Hatton R.C., Fann A.L., Baz M.A., and Kaplan B. Evaluation of drug interaction software to identify alerts for transplant medications. Ann Pharmacother 39 1 (2005) 45-50
10. Hsieh T.C., Kuperman G., Jaggi T., Hojnowski-Diaz P., Fiskio J., Williams D., et al. Characteristics and consequences of drug allergy alert overrides in a computerized physician order entry system. JAMIA 11 6 (2004) 482-491
11. Hansten P. Drug interaction management. Pharm World Sci 25 3 (2003) 94-97
12. Bergk V., Haefeli W., Gasse C., Brenner H., and Martin-Facklam M. Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: a comparison with evidence from the literature. Eur J Clin Pharmacol 61 5-6 (2005) 327-335
13. van der Sijs H., Aarts J., Vulto A., and Berg M. Overriding of drug safety alerts in computerized physician order entry. J Am Med Inform Assoc 13 2 (2006) 138-147
14. Reichley R., Seaton T., Resetar E., Micek S., Scott K., Fraser V., et al. Implementing a commercial rule base as a medication order safety net. JAMIA 12 4 (2005) 383-389 PubMed ID:1580248
15. Internal Authorship. FDA guideline: Drug interaction studies-study design, data analysis, and implications for dosing and labeling, Internet, Last accessed 09/25/2006, September 2006. Available from: http://www.fda.gov/Cber/gdlns/interactstud.htm.
16. Boyce R, Collins C, Horn J, Kalet I. Qualitative pharmacokinetic modeling of drugs. In: Proceedings of the AMIA; 2005. p. 71-5.
17. Boyce R., Collins C., Horn J., and Kalet I. Modeling drug mechanism knowledge using evidence and truth maintenance. IEEE Trans Inform Technol Biomed 11 4 (2007) 386-397
18. Rubin D.L., Carrillo M., Woon M., Conroy J., Klein T.E., Altman R.B., et al. Medinfo 11 Pt 2 (2004) 793-797
19. Internal Authorship, Medical Subject Headings Publication Types, Internet, Last accessed 05/14/2008, 2008. http://www.nlm.nih.gov/mesh/pubtypes2008.html.
20. Gene Ontology Consortium, The GO Evidence Code Guide, Internet, Last accessed 05/12/2008, 2008. Available from: http://www.geneontology.org/GO.evidence.shtml.
21. Karp P, Paley S, Krieger C, Zhang P. An evidence ontology for use in pathway/genome databases. In: Pacific Symposium on Biocomputing 2004. 2004; p. 190-201.
22. Altman R.B., Flockhart D.A., Sherry S.T., Oliver D.E., Rubin D.L., Klein T.E., et al. Pharmacogenetics 13 1 (2003) 3-5
23. Coletti M.H., and Bleich H.L. Medical subject headings used to search the biomedical literature. J Am Med Inform Assoc 8 4 (2001) 317-323
24. Gene Ontology Consortium. The Gene Ontology (GO) project in 2006. Nucleic Acids Research, vol. 34. Database Issue.
25. West S, King V, Carey T, Lohr K, McKoy N, Sutton S, Lux L. Systems to rate the strength of scientific evidence. Tech. Rep. 02-E016. Agency for Healthcare Research and Quality; 2002.
26. Griffin D., and Brenner L. The blackwell handbook of judgement and decision making (2004), Blackwell
27. Miller G.A. WordNet: a lexical database for English. Commun ACM 38 11 (1995) 39-41
28. de Coronado S., Haber M.W., Sioutos N., Tuttle M.S., and Wright L.W. NCI Thesaurus: using science-based terminology to integrate cancer research results. Medinfo 11 Pt 1 (2004) 33-37
29. World Wide Web Consortium. Web Ontology Language (OWL), Internet, Last accessed 02/14/2007, 2007. Available from: http://www.w3.org/2004/OWL/.
30. Haarslev V, Möller R. Racer: a core inference engine for the semantic web; 2003. p. 27-36.
31. Boyce R, Collins C, Gennari J, Horn, J, Kalet I. DIKB Ontology Internet, Last accessed 09/12/2008, 2007. http://www.pitt.edu/rdb20/data/DIKB_evidence_ontology_v1.0.owl.
32. Herman R.J., and interactions D. Drug interactions and the statins. CMAJ 161 10 (1999) 1281-1286
33. Merck, zocor (simvastatin) tablet, film coated, FDA-approved drug product labeling, last accessed on DailyMed 04/19/2008 (07/2007).
34. Merck, mevacor (lovastatin) tablet, FDA-approved drug product labeling, last accessed on DailyMed 04/19/2008 (01/2008).
35. Neuvonen P.J., and Jalava K.M. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 60 1 (1996) 54-61
36. Neuvonen P.J., Kantola T., and Kivisto K.T. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 63 3 (1998) 332-341
37. Jacobsen W., Kuhn B., Soldner A., Kirchner G., Sewing K.F., Kollman P.A., et al. Drug Metab Dispos 28 11 (2000) 1369-1378
38. Brunton L. Goodman & Gilman's the pharmacological basis of therapeutics (2006), McGraw-Hill, New York
39. Olkkola K.T., Backman J.T., and Neuvonen P.J. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55 5 (1994) 481-485
40. Varhe A., Olkkola K.T., and Neuvonen P.J. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 56 6 Pt 1 (1994) 601-607
41. Yasui N., Kondo T., Otani K., Furukori H., Kaneko S., Ohkubo T., et al. Psychopharmacology (Berl) 139 3 (1998) 269-273
42. Janssen, sporanox (itraconazole) capsule, FDA-approved drug product labeling, last accessed on DailyMed 05/16/2008 (01/2008).
43. Rubin D.L., Thorn C.F., Klein T.E., and Altman R.B. A statistical approach to scanning the biomedical literature for pharmacogenetics knowledge. J Am Med Inform Assoc 12 2 (2005) 121-129
44. Pustejovsky J, Castano J, Zhang J, Kotecki M, Cochran M. Robust relational parsing over biomedical literature: extracting inhibit relations. In: Pacific symposium on biocomputing; 2002. p. 362-73.
45. Kosuge K., Nishimoto M., Kimura M., Umemura K., Nakashima M., Ohashi K., et al. Br J Clin Pharmacol 43 4 (1997) 367-372
46. Park J.Y., Kim K.A., Park P.W., Lee O.J., Kang D.K., Shon J.H., et al. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects. Clin Pharmacol Ther 79 6 (2006) 590-599
47. Rodrigues A.D., Roberts E.M., Mulford D.J., Yao Y., and Ouellet D. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. Drug Metab Dispos 25 5 (1997) 623-630
48. Internal Authorship, FDA guidance for industry-population pharmacokinetics, Tech. rep. Federal Drug Administration; 1999.